Short answer
IRADIMED CORP (IRMD) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $24M (up 14.2% year over year) with net income of $7M.
Q3 2026 key financials · XBRL
- Revenue
- $24M
- +14.2% YoY · +18.3% QoQ
- Net income
- $7M
- +16.7% YoY · +24.7% QoQ
- Operating margin
- 33.6%
- Gross margin
- 76.3%
- EPS (diluted)
- $0.51
- +18.6% YoY · +24.4% QoQ
Source: XBRL data from the IRADIMED CORP (IRMD) Q3 2026 10-Q on SEC EDGAR. USD.
IRADIMED CORP Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $24.2M, up 14% YoY from $21.2M, driven by devices, disposables and international sales
- Vital signs monitoring revenue $8.0M, up from $6.9M, strongest product growth
- Gross margin 76% vs 78% YoY, pressured by initial new-product production inefficiencies
- Net margin 26.9% vs 26.3% YoY, with net income $6.5M vs $5.6M
- Cash $63.3M vs $51.2M; operating cash flow $21.2M vs $19.0M, financing outflow $8.0M from higher dividends
- Fiscal 2026 outlook: higher revenue and operating expenses, with tariff, supply-chain and geopolitical uncertainty remaining headwinds
Risk Factors
- No material changes from risks described in the 2025 Annual Report
- Unknown or currently immaterial risks could materially adversely affect business, financial condition, or future results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IRADIMED CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.